OBRR Lab

The Food and Drug Administration is forecasting a future procurement focused on the development of a prophylactic vaccine for visceral leishmaniasis, a serious parasitic disease. The opportunity is listed under NAICS code 423450, indicating it relates to medical and diagnostic equipment and supplies merchant wholesaling, suggesting the project may involve commercial-scale production or distribution of the vaccine. While the solicitation number and set-aside details are not yet available, the point of contact for program inquiries is Cber Acquisition Liaison at cberacquisitions@fda.hhs.gov, and the contracting officer role remains to be assigned. The place of performance and specific location details have not been specified, but the effort is expected to support public health initiatives under FDA oversight, likely requiring compliance with rigorous regulatory and manufacturing standards for vaccine delivery. The forecast was posted on May 25, 2026, signaling potential future contract issuance, though no deadline or formal solicitation has been issued yet.